These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Stage II colon cancer prognosis prediction by tumor gene expression profiling. Barrier A; Boelle PY; Roser F; Gregg J; Tse C; Brault D; Lacaine F; Houry S; Huguier M; Franc B; Flahault A; Lemoine A; Dudoit S J Clin Oncol; 2006 Oct; 24(29):4685-91. PubMed ID: 16966692 [TBL] [Abstract][Full Text] [Related]
3. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. Wang Y; Jatkoe T; Zhang Y; Mutch MG; Talantov D; Jiang J; McLeod HL; Atkins D J Clin Oncol; 2004 May; 22(9):1564-71. PubMed ID: 15051756 [TBL] [Abstract][Full Text] [Related]
4. Prognosis of stage II colon cancer by non-neoplastic mucosa gene expression profiling. Barrier A; Roser F; Boëlle PY; Franc B; Tse C; Brault D; Lacaine F; Houry S; Callard P; Penna C; Debuire B; Flahault A; Dudoit S; Lemoine A Oncogene; 2007 Apr; 26(18):2642-8. PubMed ID: 17043639 [TBL] [Abstract][Full Text] [Related]
5. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Barrier A; Boelle PY; Lemoine A; Tse C; Brault D; Chiappini F; Lacaine F; Houry S; Huguier M; Flahault A; Dudoit S Dis Colon Rectum; 2005 Dec; 48(12):2238-48. PubMed ID: 16228831 [TBL] [Abstract][Full Text] [Related]
6. Colon cancer prognosis prediction by gene expression profiling. Barrier A; Lemoine A; Boelle PY; Tse C; Brault D; Chiappini F; Breittschneider J; Lacaine F; Houry S; Huguier M; Van der Laan MJ; Speed T; Debuire B; Flahault A; Dudoit S Oncogene; 2005 Sep; 24(40):6155-64. PubMed ID: 16091735 [TBL] [Abstract][Full Text] [Related]
7. An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancer. Roepman P; Jassem J; Smit EF; Muley T; Niklinski J; van de Velde T; Witteveen AT; Rzyman W; Floore A; Burgers S; Giaccone G; Meister M; Dienemann H; Skrzypski M; Kozlowski M; Mooi WJ; van Zandwijk N Clin Cancer Res; 2009 Jan; 15(1):284-90. PubMed ID: 19118056 [TBL] [Abstract][Full Text] [Related]
8. Survival following recurrence in stage II and III colon cancer: findings from the ACCENT data set. O'Connell MJ; Campbell ME; Goldberg RM; Grothey A; Seitz JF; Benedetti JK; André T; Haller DG; Sargent DJ J Clin Oncol; 2008 May; 26(14):2336-41. PubMed ID: 18467725 [TBL] [Abstract][Full Text] [Related]
11. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Bandrés E; Malumbres R; Cubedo E; Honorato B; Zarate R; Labarga A; Gabisu U; Sola JJ; García-Foncillas J Oncol Rep; 2007 May; 17(5):1089-94. PubMed ID: 17390049 [TBL] [Abstract][Full Text] [Related]
12. Survival in stage III colon cancer is independent of the total number of lymph nodes retrieved. Tsikitis VL; Larson DL; Wolff BG; Kennedy G; Diehl N; Qin R; Dozois EJ; Cima RR J Am Coll Surg; 2009 Jan; 208(1):42-7. PubMed ID: 19228501 [TBL] [Abstract][Full Text] [Related]
13. Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Maher SG; Gillham CM; Duggan SP; Smyth PC; Miller N; Muldoon C; O'Byrne KJ; Sheils OM; Hollywood D; Reynolds JV Ann Surg; 2009 Nov; 250(5):729-37. PubMed ID: 19801928 [TBL] [Abstract][Full Text] [Related]
14. Local recurrence in mismatch repair-proficient colon cancer predicted by an infiltrative tumor border and lack of CD8+ tumor-infiltrating lymphocytes. Zlobec I; Terracciano LM; Lugli A Clin Cancer Res; 2008 Jun; 14(12):3792-7. PubMed ID: 18559598 [TBL] [Abstract][Full Text] [Related]
15. Predicting clinical outcome through molecular profiling in stage III melanoma. John T; Black MA; Toro TT; Leader D; Gedye CA; Davis ID; Guilford PJ; Cebon JS Clin Cancer Res; 2008 Aug; 14(16):5173-80. PubMed ID: 18698035 [TBL] [Abstract][Full Text] [Related]
16. Final results of a randomised phase III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. Dahl O; Fluge Ø; Carlsen E; Wiig JN; Myrvold HE; Vonen B; Podhorny N; Bjerkeset O; Eide TJ; Halvorsen TB; Tveit KM; Acta Oncol; 2009; 48(3):368-76. PubMed ID: 19242829 [TBL] [Abstract][Full Text] [Related]
17. Loss of Bcl-2 expression in colon cancer: a prognostic factor for recurrence in stage II colon cancer. Poincloux L; Durando X; Seitz JF; Thivat E; Bardou VJ; Giovannini MH; Parriaux D; Barriere N; Giovannini M; Delpero JR; Monges G Surg Oncol; 2009 Dec; 18(4):357-65. PubMed ID: 19027288 [TBL] [Abstract][Full Text] [Related]
18. A 38-gene expression signature to predict metastasis risk in node-positive breast cancer after systemic adjuvant chemotherapy: a genomic substudy of PACS01 clinical trial. Jézéquel P; Campone M; Roché H; Gouraud W; Charbonnel C; Ricolleau G; Magrangeas F; Minvielle S; Genève J; Martin AL; Bataille R; Campion L Breast Cancer Res Treat; 2009 Aug; 116(3):509-20. PubMed ID: 19020972 [TBL] [Abstract][Full Text] [Related]
19. Multigene assays to improve assessment of recurrence risk and benefit from chemotherapy in early-stage colon cancer: has the time finally arrived, or are we still stage locked? Tabernero J; Baselga J J Clin Oncol; 2010 Sep; 28(25):3904-7. PubMed ID: 20679612 [No Abstract] [Full Text] [Related]
20. Development and independent validation of a prognostic assay for stage II colon cancer using formalin-fixed paraffin-embedded tissue. Kennedy RD; Bylesjo M; Kerr P; Davison T; Black JM; Kay EW; Holt RJ; Proutski V; Ahdesmaki M; Farztdinov V; Goffard N; Hey P; McDyer F; Mulligan K; Mussen J; O'Brien E; Oliver G; Walker SM; Mulligan JM; Wilson C; Winter A; O'Donoghue D; Mulcahy H; O'Sullivan J; Sheahan K; Hyland J; Dhir R; Bathe OF; Winqvist O; Manne U; Shanmugam C; Ramaswamy S; Leon EJ; Smith WI; McDermott U; Wilson RH; Longley D; Marshall J; Cummins R; Sargent DJ; Johnston PG; Harkin DP J Clin Oncol; 2011 Dec; 29(35):4620-6. PubMed ID: 22067406 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]